Dry Eye Disease: Considerations for Health System Pharmacists

Dry Eye Disease: Considerations for Health System Pharmacists

On-Demand Webcast

This webcast is based on live proceedings from the Pharmacy Learning Network 2016 Conference Series. 

Participants who have successfully completed the live version of this activity are not eligible to receive credit for this enduring material.

Faculty

Randall Seifert, PharmD
Senior Associate Dean
University of Minnesota College of Pharmacy
Professor, Pharmacy Practice and Pharmaceutical Sciences
Duluth, Minnesota

Intended Learners

This activity is designed for health-system pharmacists.

Learning Objectives

After completing this activity, participants should be able to:

  • Identify factors that increase risk for DED and indicate referral to an eye specialist as needed
  • Evaluate the use of recently developed pharmacologic treatment options for DED in patient-centered treatment strategies and placement within current treatment recommendations
  • Implement strategies to support patient counseling, education on DED pathophysiology and treatments, and patient access to newly available therapeutic options
  • Describe the current and emerging role of the pharmacist in the management of DED
Activity Overview

This on-demand webcast is available with synchronized slides and video.

To be eligible for documentation of credit, participants must complete the educational activity, complete the 10-question online post-test with a score of 70% or better, and complete the evaluation form. After successful completion of the post-test and evaluation form online at www.naccme.com, participants may immediately print their documentation of credit.

ACPE Credit Policy

Your official record of ACPE credit will be generated through the CPE Monitor System. The certificate printed from this website after completing the evaluation for this activity is for personal tracking purposes only.

Eligibility for pharmacy credit is contingent upon the successful completion of a post-test and/or evaluation for each activity or session attended. Please note that you must complete the activity evaluation within 60 days of a live activity or within 60 days of beginning the evaluation for an enduring activity. Under ACPE Policy, NACCME will not be able to report your activity completion to CPE Monitor after this 60-day period.

Release Date: December 20, 2016
Expiration Date: December 20, 2017
Estimated time to complete: 45 minutes

There is no fee associated with this activity.

Participants who have successfully completed the live version of this activity are not eligible to receive credit for this enduring material.

For questions regarding this educational activity, please call 609-371-1137.

Hardware/Software Requirements

All educational activities are accessible via a PC (Windows 2000/XP/Vista/7) or Mac (Mac OS 10.x or later) computer with current versions of the following browsers: Internet Explorer, Mozilla Firefox, Google Chrome, or Safari. Windows Media Player or compatible alternative, sound card, and speakers are required for streamed audio. The latest version of the Adobe Flash Player is suggested for video programs (please download here). A PDF reader is required for print publications. Please direct technical questions to webmaster@naccme.com.

Accreditation

In support of improving patient care, North American Center for Continuing Medical Education (NACCME) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

CPE

This activity is approved for 0.75 contact hour (.075 CEUs) of continuing pharmacy education (0276-0000-16-093-H01-P).

This educational activity is a knowledge-based activity.

Any participant wanting to file a grievance with respect to any aspect of a continuing pharmacy education activity accredited by NACCME may contact the Senior Manager, Accreditation & Compliance, NACCME, in writing at 104 Windsor Center Drive, East Windsor, NJ 08520. The Senior Manager, Accreditation & Compliance will review the grievance and respond within 30 days of receiving the written statement. If the participant is unsatisfied with the response, an appeal to the Senior Director, Accreditation and Compliance, NACCME, may be made for a second level of review.

Independent Clinical Reviewer: Kyle R. Copeland, PharmD, Clinical Specialist Pharmacist, Parkwest Medical Center, Assistant Professor, University of Tennessee College of Pharmacy, Knoxville, Tennessee

Planning Committee

The planning committee comprises Randall Seifert, PharmD, Kyle R. Copeland, PharmD; and Donna Brophy, Kristin Ciszeski, Mary Johnson, Michael Kearney, Susan Kuhn, Michelle Montgomery, Randy Robbin, John Savage, and Sydney Turner, NACCME.

Financial Disclosure and Conflicts of Interest

According to the disclosure policy of NACCME, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of NACCME to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.

All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

The faculty have disclosed the following:

Dr. Copeland and Dr. Seifert have disclosed no relevant financial relationships with any commercial interests.

Ms. Brophy, Ms. Ciszeski, Ms. Johnson, Mr. Kearney, Ms. Montgomery, Mr. Robbin, Mr. Savage and Ms. Turner have disclosed no relevant financial relationships with any commercial interests.

Ms. Kuhn: Stock Shareholder (spouse)—Osiris Pharmaceuticals

NACCME requires faculty to inform participants whenever off-label/unapproved uses of drugs and/or devices are discussed in their presentations.

This continuing education activity includes medication brand names for participant clarity purposes only. No product promotion or recommendations should be inferred.

Privacy Policy

NACCME protects the privacy of personal and other information regarding participants, educational partners, and joint sponsors. NACCME and our joint sponsors will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the appropriate accrediting agency.

NACCME maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Copyright © 2016 by North American Center for Continuing Medical Education, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from North American Center for Continuing Medical Education. The opinions expressed in this educational activity are those of the faculty and are not attributable to NACCME. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.

Grant Support

This activity is supported by an educational grant from Shire.